Jiayi Wu
The University of Melbourne(AU)City University of Hong Kong(HK)Beijing University of Chinese Medicine(CN)Nankai University(CN)Fudan University(CN)Ministry of Education(KR)Guangzhou First People's Hospital(CN)First Affiliated Hospital of University of South China(CN)Zhejiang University(CN)University of South China(CN)Guangzhou Medical University(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Cancer-related Molecular Pathways, PARP inhibition in cancer therapy, DNA Repair Mechanisms, Angiogenesis and VEGF in Cancer
Most-Cited Works
- → EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity(2017)92 cited
- → E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling(2015)84 cited
- → Cytoplasmic FMR1-Interacting Protein 2 Is a Major Genetic Factor Underlying Binge Eating(2016)82 cited
- → Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status(2012)45 cited
- → Fertility and Neonatal Outcomes of Freeze-All vs. Fresh Embryo Transfer in Women With Advanced Endometriosis(2019)36 cited
- → Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms(2018)